Molecule licensing and acquisition deals are key strategies to expand pipelines and enter new markets or therapeutic areas. Whether the transaction involves a regional licensing agreement, a full asset acquisition, or anything in between, a successful deal often hinges on the strength and readiness of the Chemistry, Manufacturing, and Controls (CMC) package. Performing thorough CMC due diligence helps sponsors understand the readiness of a molecule for its intended phase or market and whether there are CMC risks that could lead to post-acquisition remediation efforts.
Types of Transactions
The focus of a CMC due diligence effort will shift depending on the deal structure as different deal structures drive different CMC expectations.
- Regional Licensing: When a product is licensed for marketing in a new region, the CMC package should be assessed for regional regulatory requirements. For example, EU QP release requirements or PUPSIT (Pre-use Post-Sterilization Integrity Testing) expectations may not have been addressed for a program intended for submission outside of the EU.
- Indication Expansion: For licensing of a molecule for a new indication, it is critical to confirm that the manufacturing process is robust and phase-appropriate to support the expanded clinical and regulatory scope. Proactively assessing scalability and CMC readiness helps mitigate the risk of redevelopment work or regulatory delays.
- Asset Acquisition: In a complete transfer of asset ownership, the buyer assumes all historical CMC risk. Thorough due diligence is critical to identify any unresolved gaps in the CMC strategy that could hold back regulatory approval or commercial scalability.
What is Evaluated during Due Diligence?
A comprehensive CMC due diligence evaluation assess both suitability (is the CMC package appropriate for the intended phase of development?) and gaps (what is missing that could delay approval or commercialization?).
Regulatory Submissions
- IND Review: Evaluate whether early-phase manufacturing controls and analytical methods are adequate for Phase 1/2 and can support future development.
- NDA/BLA Readiness: For later-stage programs, assess whether the package meets expectations for approval and can support commercial activities.
Process and Analytical Readiness
- Cell Line Development: Determine if the cell line has been adequately characterized and documented.
- Manufacturing Control Strategy: Assess process robustness, critical process parameters, and scale-up data.
- Process Validation: Evaluate the status of process validation along with phase appropriate filter validation.
- Analytical Methods and Characterization: Are the method qualifications/validations phase-appropriate? Does characterization supports product understanding?
- Reference Standard: What is the current state of reference standard qualification and what are the inventory levels?
- Specifications: Are the specifications justified and phase-appropriate?
- Process and Analytical Comparability: Ensure manufacturing changes are supported by comparability data.
Quality and Compliance
- Stability Data: Review existing stability data and trending and assess potential stability gaps that may impact shelf life.
- Nitrosamine Risk Assessment: Has a phase-appropriate nitrosamine risk assessment been performed and do the conclusions alignment with evolving regulatory expectations?
- Response to FDA Feedback: Have CMC information requests or deficiencies been sufficiently addressed?
- QP Release and Inspection History: Evaluate EU QP release records and manufacturing site inspection outcomes, which may influence regulatory confidence and market entry.
Operational Readiness
- Clinical Batch Availability: What is the availability and suitability of clinical material for ongoing trials, bridging studies, or future trials?
- Technology Transfer Support: Assess adequacy of documentation, analytical methods, and personnel support to support tech transfer to a new manufacturing site or partner.
Common CMC Findings Linked to Complete Response Letters
A key goal during due diligence is to identify red flags that have historically led to Complete Response Letters (CRLs) or delayed approvals including:
- Incomplete process validation or insufficient process control documentation.
- Gaps in analytical method validation.
- Lack of comparability data following manufacturing process changes.
- Inadequate risk assessments for impurities or degradation products (e.g., nitrosamines).
- Missing regional compliance elements such as PUPSIT, QP release, or site inspection readiness.
Identifying these common findings during due diligence allows sponsors to better understand remediation costs and plan development timelines accordingly.
Conclusion
CMC due diligence is critical for evaluating the value and timing of licensing or acquisition deals. A thorough assessment by experienced CMC experts provides insight into an asset’s technical and regulatory readiness and enables informed decisions about the future success of a molecule’s development and marketing.
Partner with Syner-G for Expert CMC Due Diligence
At Syner-G, our multidisciplinary CMC experts help clients navigate the complexities of molecule licensing and acquisitions with confidence. We provide comprehensive CMC due diligence evaluations covering process development, analytical readiness, regulatory compliance, and quality assurance. Whether you are assessing an early-phase candidate or a commercial-stage asset, Syner-G delivers the technical insight and strategic guidance needed to identify risks, quantify remediation needs, and accelerate deal success. Contact us today to learn how we can strengthen your next transaction.
